DCTH Earnings Date: Nov 9, 2026 (Estimated) — Delcath Systems, Inc.
NASDAQ · Healthcare · Medical Devices
Updated
When is DCTH's next earnings date?
Delcath Systems, Inc. (DCTH) is expected to report Q3 2026 earnings on Monday, November 9, 2026 at 8:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.10 on revenue of $26.0M.
How did DCTH do in its last earnings report?
In its most recent report on Aug 6, 2026 (Q2 2026), Delcath Systems, Inc. posted EPS of $0.07 versus the -$0.09 estimate, a beat of 170.0%. Revenue was $29.1M against a $26.3M estimate. The stock's 1-day post-earnings move was +22.5%.
How much does DCTH stock move after earnings?
DCTH beat EPS estimates in 6 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 9.2% (up or down) in the day after earnings.
About Delcath Systems, Inc.
Delcath Systems, Inc. is an interventional oncology firm operating in the United States and Europe, dedicated to developing treatments for both primary and secondary liver cancers. Its leading investigational product is the HEPZATO KIT, a unique hepatic delivery system for melphalan that targets high-dose chemotherapy specifically to the liver. This innovative approach aims to substantially reduce systemic drug exposure and mitigate associated side effects. HEPZATO's clinical evaluation is advancing through the FOCUS trial, which is designed to assess the objective response rate in individuals with metastatic uveal melanoma whose disease is primarily concentrated in the liver. Furthermore, the company offers a separate version of HEPZATO as a medical device in Europe, marketed under the CHEMOSAT Hepatic Delivery System brand (or simply CHEMOSAT). This system empowers European medical centers to manage a diverse array of liver cancer conditions. Delcath Systems, Inc. was established in 1988, with its corporate headquarters situated in New York, New York.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-06 | Q2 2026 | -0.09 | 0.07 | +170.00% | $29.1M | ✅ Beat | +22.49% | +35.47% | +30.48% |
| 2026-05-07 | Q1 2026 | -0.08 | -0.03 | +62.50% | $25.0M | ✅ Beat | -0.18% | +3.11% | -5.24% |
| 2026-02-26 | Q4 2025 | -0.04 | -0.05 | -25.00% | $20.7M | ❌ Miss | -11.85% | -9.60% | -10.58% |
| 2025-11-04 | Q3 2025 | -0.05 | 0.02 | +140.00% | $20.6M | ✅ Beat | -4.62% | -9.87% | +1.47% |
| 2025-08-06 | Q2 2025 | 0.02 | 0.07 | +250.00% | $24.2M | ✅ Beat | +1.14% | +3.42% | +5.51% |
| 2025-03-06 | Q4 2024 | -0.02 | -0.11 | -450.00% | $15.1M | ❌ Miss | -1.56% | -9.08% | -10.65% |
| 2024-11-08 | Q3 2024 | -0.20 | 0.06 | +130.00% | $11.2M | ✅ Beat | +1.10% | -15.63% | +5.85% |
| 2024-05-14 | Q1 2024 | -0.47 | -0.45 | +4.26% | $3.1M | ✅ Beat | +30.93% | +48.70% | +32.78% |
Showing last 8 quarters.
Revenue by segment & region
By region
Q2 FY26 · $29.1M total
| Segment | Share | Revenue | YoY | Q2 FY26 |
|---|---|---|---|---|
| UNITED STATES | 93.2% | $27.2M | — | $27.2M |
| Non-US | 6.8% | $2.0M | — | $2.0M |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.